Vivus strengthens executive leadership team

Vivus a biopharmaceutical company, has appointed three executives to the company's senior leadership team.

John Amos has joined as the company's new CEO and a new member of the company's board of directors.

"Vivus has an exciting portfolio of specialty pharmaceutical products as well as significant development, regulatory and commercialization expertise, which I believe can be leveraged to create additional long-term value," said John Amos, CEO at Vivus.

"I am excited to join the company, as are Ken and Scott. We look forward to working with the dedicated employees at Vivus who have already commercialized several important specialty pharmaceutical products. Combining this dedicated team with new products that contribute meaningful revenue growth will put Vivus on the path to becoming a leading profitable specialty pharmaceutical company in the future."

Scott Oehrlein is COO, a newly created position within the company. Kenneth Suh will continue as president and CEO of Willow Biopharma, now a wholly-owned subsidiary of Vivus.

"When I founded Willow Biopharma, I believed that another significant ethical pharmaceutical company could be created through disciplined deal making and building a portfolio of pharmaceutical brands and products to meet patients' needs. By integrating with Vivus, we believe we can accelerate this vision," said Kenneth Suh, President and CEO at Willow Biopharma.

All three executives were previously members of the senior leadership team at Willow Biopharma, a specialty pharmaceutical company based in Toronto, Canada.

Thomas B. King, who today assumed a new position as Interim President, to facilitate this management transition, said: "John, Ken and Scott each have a long track record of creating value in the pharmaceutical industry by effectively identifying, commercializing and marketing best-in-class therapies."

"We are confident that this team, working collaboratively with our existing senior leadership, is well-positioned to create long-term value for Vivus patients and stockholders."

You may also like